Brown Advisory Securities LLC Trims Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Brown Advisory Securities LLC trimmed its holdings in DexCom, Inc. (NASDAQ:DXCM – Get Rating) by 26.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 460 shares of the medical device company’s stock after selling 169 shares during the period. Brown Advisory Securities LLC’s holdings in DexCom were worth $235,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of DXCM. Van ECK Associates Corp purchased a new position in DexCom in the 4th quarter valued at approximately $165,000. CWM LLC purchased a new position in DexCom in the 4th quarter valued at approximately $153,000. Centaurus Financial Inc. grew its stake in DexCom by 4.9% in the 4th quarter. Centaurus Financial Inc. now owns 1,172 shares of the medical device company’s stock valued at $629,000 after buying an additional 55 shares in the last quarter. FDx Advisors Inc. purchased a new position in DexCom in the 4th quarter valued at approximately $473,000. Finally, Pinnacle Financial Partners Inc. purchased a new position in DexCom in the 4th quarter valued at approximately $268,000. 93.26% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Jereme M. Sylvain sold 600 shares of the company’s stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $301.57, for a total transaction of $180,942.00. Following the completion of the transaction, the chief financial officer now directly owns 17,408 shares of the company’s stock, valued at $5,249,730.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CFO Jereme M. Sylvain sold 600 shares of the company’s stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $301.57, for a total transaction of $180,942.00. Following the completion of the transaction, the chief financial officer now directly owns 17,408 shares of the company’s stock, valued at $5,249,730.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Chad Patterson sold 777 shares of the company’s stock in a transaction dated Monday, May 9th. The shares were sold at an average price of $342.77, for a total transaction of $266,332.29. Following the transaction, the executive vice president now directly owns 13,675 shares of the company’s stock, valued at $4,687,379.75. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,627 shares of company stock valued at $676,977. Insiders own 0.41% of the company’s stock.

DexCom Stock Performance

DexCom stock opened at $89.09 on Friday. The company has a quick ratio of 4.30, a current ratio of 4.72 and a debt-to-equity ratio of 0.87. The company has a market capitalization of $34.97 billion, a PE ratio of 185.61, a P/E/G ratio of 3.58 and a beta of 1.03. The firm has a fifty day simple moving average of $86.60 and a two-hundred day simple moving average of $98.48. DexCom, Inc. has a twelve month low of $66.89 and a twelve month high of $164.86.

DexCom (NASDAQ:DXCM – Get Rating) last posted its quarterly earnings results on Thursday, July 28th. The medical device company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.02). The business had revenue of $696.20 million during the quarter, compared to the consensus estimate of $709.33 million. DexCom had a return on equity of 11.79% and a net margin of 7.47%. The business’s revenue for the quarter was up 17.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.19 earnings per share. Research analysts expect that DexCom, Inc. will post 0.8 EPS for the current year.

Analysts Set New Price Targets

DXCM has been the subject of a number of recent analyst reports. Citigroup reduced their price target on shares of DexCom from $105.00 to $100.00 in a research report on Friday, July 29th. Wells Fargo & Company reduced their price target on shares of DexCom from $144.00 to $102.00 in a research report on Friday, July 29th. Robert W. Baird reduced their price target on shares of DexCom from $115.00 to $97.00 in a research report on Friday, July 29th. SVB Leerink reduced their price target on shares of DexCom from $141.25 to $125.00 in a research report on Friday, April 29th. Finally, BTIG Research reduced their price target on shares of DexCom from $135.00 to $105.00 and set a “buy” rating for the company in a research report on Friday, June 24th. Two equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $115.23.

DexCom Profile

(Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.